{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/utkarshbelkhede/Financial_Dashboard/blob/master/notebooks/7_Final_DF_using_Custom_HuggingFace_Model.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#### 1. Setting up Working Directory"
      ],
      "metadata": {
        "id": "c5NdRZ_Iq227"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from google.colab import drive\n",
        "\n",
        "drive.mount('/content/drive')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "8ocNLJakMX-b",
        "outputId": "efd5f8d9-ee44-447a-b298-b60542a567ff"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Mounted at /content/drive\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Working Directory\n",
        "import os\n",
        "\n",
        "os.chdir('/content/drive/MyDrive/Documents/Market Intelligence')"
      ],
      "metadata": {
        "id": "rpDjmYfxEubg"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#### 2. Config"
      ],
      "metadata": {
        "id": "bYywltLaq-RO"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "COMBINED_CSV = \"./datasets/final_combined_dataset.csv\"\n",
        "SUMARIZED_MODEL = \"sshleifer/distilbart-cnn-12-6\"\n",
        "CLASSIFIED_MODEL = \"distilbert-base-uncased-finetuned-sst-2-english\""
      ],
      "metadata": {
        "id": "JVKj-Yf8kKyD"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "#### 3. Dataframe"
      ],
      "metadata": {
        "id": "oqR0hRpLrKHw"
      }
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "xNgkkd4e1Lmd"
      },
      "outputs": [],
      "source": [
        "import pandas as pd\n",
        "import re"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 597
        },
        "id": "RHh2l7zc1bMh",
        "outputId": "5f65ffe6-767b-459b-fb0d-58a90d59f084"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "  Company  Reporting_Date                                                  1  \\\n",
              "0    Meta            2021   Item 1. Business Overview Our mission is to g...   \n",
              "1    Meta            2020   Item 1. Business Overview Our mission is to g...   \n",
              "2    Meta            2019   Item 1. Business Overview Our mission is to g...   \n",
              "3    Meta            2018   Item 1. Business Overview Our mission is to g...   \n",
              "4    Meta            2017   Item 1. Business Overview Our mission is to g...   \n",
              "\n",
              "                                                  1A  \\\n",
              "0   Item 1A. Risk Factors Certain factors may hav...   \n",
              "1   Item 1A. Risk Factors Certain factors may hav...   \n",
              "2   Item 1A. Risk Factors Certain factors may hav...   \n",
              "3   Item 1A. Risk Factors Certain factors may hav...   \n",
              "4   Item 1A. Risk Factors Certain factors may hav...   \n",
              "\n",
              "                                           1B  \\\n",
              "0   Item 1B. Unresolved Staff Comments None.    \n",
              "1   Item 1B. Unresolved Staff Comments None.    \n",
              "2   Item 1B. Unresolved Staff Comments None.    \n",
              "3   Item 1B. Unresolved Staff Comments None.    \n",
              "4   Item 1B. Unresolved Staff Comments None.    \n",
              "\n",
              "                                                   2  \\\n",
              "0   Item 2. Properties Our corporate headquarters...   \n",
              "1   Item 2. Properties  Our corporate headquarter...   \n",
              "2   Item 2. Properties  Our corporate headquarter...   \n",
              "3   Item 2. Properties  Our corporate headquarter...   \n",
              "4   Item 2. Properties  Our corporate headquarter...   \n",
              "\n",
              "                                                   3  \\\n",
              "0   Item 3. Legal Proceedings Beginning on March ...   \n",
              "1   Item 3. Legal Proceedings Beginning on March ...   \n",
              "2   Item 3. Legal Proceedings Beginning on March ...   \n",
              "3   Item 3. Legal Proceedings Beginning on March ...   \n",
              "4   Item 3. Legal Proceedings Beginning on May 22...   \n",
              "\n",
              "                                                   5  \\\n",
              "0   Item 5. Market for Registrant's Common Equity...   \n",
              "1   Item 5. Market for Registrant's Common Equity...   \n",
              "2   Item 5. Market for Registrant's Common Equity...   \n",
              "3   Item 5. Market for Registrant's Common Equity...   \n",
              "4   Item 5. Market for Registrant's Common Equity...   \n",
              "\n",
              "                                                   7  \\\n",
              "0   Item 7. Management's Discussion and Analysis ...   \n",
              "1   Item 7. Management's Discussion and Analysis ...   \n",
              "2   Item 7. Management's Discussion and Analysis ...   \n",
              "3   Item 7. Management's Discussion and Analysis ...   \n",
              "4   Item 7. Management's Discussion and Analysis ...   \n",
              "\n",
              "                                                  7A  \\\n",
              "0   Item 7A. Quantitative and Qualitative Disclos...   \n",
              "1   Item 7A. Quantitative and Qualitative Disclos...   \n",
              "2   Item 7A. Quantitative and Qualitative Disclos...   \n",
              "3   Item 7A. Quantitative and Qualitative Disclos...   \n",
              "4   Item 7A. Quantitative and Qualitative Disclos...   \n",
              "\n",
              "                                                   8  \\\n",
              "0   Item 8. Financial Statements and Supplementar...   \n",
              "1   Item 8. Financial Statements and Supplementar...   \n",
              "2   Item 8. Financial Statements and Supplementar...   \n",
              "3   Item 8. Financial Statements and Supplementar...   \n",
              "4   Item 8. Financial Statements and Supplementar...   \n",
              "\n",
              "                                                  9A  \n",
              "0   Item 9A. Controls and Procedures Evaluation o...  \n",
              "1   Item 9A. Controls and Procedures Evaluation o...  \n",
              "2   Item 9A. Controls and Procedures Evaluation o...  \n",
              "3   Item 9A. Controls and Procedures Evaluation o...  \n",
              "4   Item 9A. Controls and Procedures Evaluation o...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-8b44a384-022e-4453-a9a2-67a0a9ccd497\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Company</th>\n",
              "      <th>Reporting_Date</th>\n",
              "      <th>1</th>\n",
              "      <th>1A</th>\n",
              "      <th>1B</th>\n",
              "      <th>2</th>\n",
              "      <th>3</th>\n",
              "      <th>5</th>\n",
              "      <th>7</th>\n",
              "      <th>7A</th>\n",
              "      <th>8</th>\n",
              "      <th>9A</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2021</td>\n",
              "      <td>Item 1. Business Overview Our mission is to g...</td>\n",
              "      <td>Item 1A. Risk Factors Certain factors may hav...</td>\n",
              "      <td>Item 1B. Unresolved Staff Comments None.</td>\n",
              "      <td>Item 2. Properties Our corporate headquarters...</td>\n",
              "      <td>Item 3. Legal Proceedings Beginning on March ...</td>\n",
              "      <td>Item 5. Market for Registrant's Common Equity...</td>\n",
              "      <td>Item 7. Management's Discussion and Analysis ...</td>\n",
              "      <td>Item 7A. Quantitative and Qualitative Disclos...</td>\n",
              "      <td>Item 8. Financial Statements and Supplementar...</td>\n",
              "      <td>Item 9A. Controls and Procedures Evaluation o...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2020</td>\n",
              "      <td>Item 1. Business Overview Our mission is to g...</td>\n",
              "      <td>Item 1A. Risk Factors Certain factors may hav...</td>\n",
              "      <td>Item 1B. Unresolved Staff Comments None.</td>\n",
              "      <td>Item 2. Properties  Our corporate headquarter...</td>\n",
              "      <td>Item 3. Legal Proceedings Beginning on March ...</td>\n",
              "      <td>Item 5. Market for Registrant's Common Equity...</td>\n",
              "      <td>Item 7. Management's Discussion and Analysis ...</td>\n",
              "      <td>Item 7A. Quantitative and Qualitative Disclos...</td>\n",
              "      <td>Item 8. Financial Statements and Supplementar...</td>\n",
              "      <td>Item 9A. Controls and Procedures Evaluation o...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2019</td>\n",
              "      <td>Item 1. Business Overview Our mission is to g...</td>\n",
              "      <td>Item 1A. Risk Factors Certain factors may hav...</td>\n",
              "      <td>Item 1B. Unresolved Staff Comments None.</td>\n",
              "      <td>Item 2. Properties  Our corporate headquarter...</td>\n",
              "      <td>Item 3. Legal Proceedings Beginning on March ...</td>\n",
              "      <td>Item 5. Market for Registrant's Common Equity...</td>\n",
              "      <td>Item 7. Management's Discussion and Analysis ...</td>\n",
              "      <td>Item 7A. Quantitative and Qualitative Disclos...</td>\n",
              "      <td>Item 8. Financial Statements and Supplementar...</td>\n",
              "      <td>Item 9A. Controls and Procedures Evaluation o...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2018</td>\n",
              "      <td>Item 1. Business Overview Our mission is to g...</td>\n",
              "      <td>Item 1A. Risk Factors Certain factors may hav...</td>\n",
              "      <td>Item 1B. Unresolved Staff Comments None.</td>\n",
              "      <td>Item 2. Properties  Our corporate headquarter...</td>\n",
              "      <td>Item 3. Legal Proceedings Beginning on March ...</td>\n",
              "      <td>Item 5. Market for Registrant's Common Equity...</td>\n",
              "      <td>Item 7. Management's Discussion and Analysis ...</td>\n",
              "      <td>Item 7A. Quantitative and Qualitative Disclos...</td>\n",
              "      <td>Item 8. Financial Statements and Supplementar...</td>\n",
              "      <td>Item 9A. Controls and Procedures Evaluation o...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2017</td>\n",
              "      <td>Item 1. Business Overview Our mission is to g...</td>\n",
              "      <td>Item 1A. Risk Factors Certain factors may hav...</td>\n",
              "      <td>Item 1B. Unresolved Staff Comments None.</td>\n",
              "      <td>Item 2. Properties  Our corporate headquarter...</td>\n",
              "      <td>Item 3. Legal Proceedings Beginning on May 22...</td>\n",
              "      <td>Item 5. Market for Registrant's Common Equity...</td>\n",
              "      <td>Item 7. Management's Discussion and Analysis ...</td>\n",
              "      <td>Item 7A. Quantitative and Qualitative Disclos...</td>\n",
              "      <td>Item 8. Financial Statements and Supplementar...</td>\n",
              "      <td>Item 9A. Controls and Procedures Evaluation o...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-8b44a384-022e-4453-a9a2-67a0a9ccd497')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-8b44a384-022e-4453-a9a2-67a0a9ccd497 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-8b44a384-022e-4453-a9a2-67a0a9ccd497');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 4
        }
      ],
      "source": [
        "df = pd.read_csv(COMBINED_CSV)\n",
        "df = df.iloc[:,1:]\n",
        "df.head()"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#### 4. Remove Duplicate\n"
      ],
      "metadata": {
        "id": "MFxhmLJxrWQv"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def remove_duplicate_sentence(df, exclude_columns):\n",
        "  \"\"\"\n",
        "  Removes duplicate sentences from columns.\n",
        "  And Returns a Clean Dataframe.\n",
        "\n",
        "  Parameters :\n",
        "  -----------\n",
        "  df: pandas.DataFrame - DataFrame on which you wish to perform Text-Preprocessing.\n",
        "  exclude_columns: int - Number of columns to exclude. (Left-to-Right)\n",
        "  \"\"\"\n",
        "\n",
        "  temp1 = df.iloc[:,:exclude_columns]\n",
        "  arr = df.iloc[:,exclude_columns:].to_numpy()\n",
        "  columns=list(df.iloc[:,exclude_columns:].columns)\n",
        "  \n",
        "  for row in range(len(arr)):\n",
        "    for col in range(len(arr[0])):\n",
        "      arr[row][col] = re.split(r\"(?<!\\w\\.\\w.)(?<![A-Z][a-z]\\.)(?<=\\.|\\?)\\s\", arr[row][col])\n",
        "\n",
        "  for row in range(len(arr[0])):\n",
        "    for col in range(len(arr)-1):\n",
        "      arr[col][row], arr[col+1][row] = [i for i in arr[col][row] if i not in arr[col+1][row]], [j for j in arr[col+1][row] if j not in arr[col][row]]\n",
        "\n",
        "  for row in range(len(arr)):\n",
        "    for col in range(len(arr[0])):\n",
        "      arr[row][col] = '. '.join(map(str, list(arr[row][col])))\n",
        "  \n",
        "  temp2 = pd.DataFrame(arr, columns=columns)\n",
        "\n",
        "  return pd.concat([temp1, temp2], axis=1)"
      ],
      "metadata": {
        "id": "KndXGwyEPn6C"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def remove_duplicate_sentence_set(df, exclude_columns):\n",
        "  \"\"\"\n",
        "  Removes duplicate sentences from columns.(Uses Set)\n",
        "  And Returns a Clean Dataframe.\n",
        "\n",
        "  Parameters :\n",
        "  -----------\n",
        "  df: pandas.DataFrame - DataFrame on which you wish to perform Text-Preprocessing.\n",
        "  exclude_columns: int - Number of columns to exclude. (Left-to-Right)\n",
        "  \"\"\"\n",
        "\n",
        "  temp1 = df.iloc[:,:exclude_columns]\n",
        "  arr = df.iloc[:,exclude_columns:].to_numpy()\n",
        "  columns=list(df.iloc[:,exclude_columns:].columns)\n",
        "\n",
        "  text_set = {''}\n",
        "\n",
        "  for row in range(len(arr)):\n",
        "    for col in range(len(arr[0])):\n",
        "      arr[row][col] = set(re.split(r\"(?<!\\w\\.\\w.)(?<![A-Z][a-z]\\.)(?<=\\.|\\?)\\s\", arr[row][col]))\n",
        "      text_set = text_set | arr[row][col]\n",
        "\n",
        "  for row in range(len(arr)):\n",
        "    for col in range(len(arr[0])):\n",
        "      arr[row][col] = arr[row][col] & text_set\n",
        "      arr[row][col] = '. '.join(map(str, list(arr[row][col])))\n",
        "  \n",
        "  temp2 = pd.DataFrame(arr, columns=columns)\n",
        "\n",
        "  return pd.concat([temp1, temp2], axis=1)"
      ],
      "metadata": {
        "id": "TBKod6h-UWC7"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "clean = remove_duplicate_sentence(df=df, exclude_columns=2)\n",
        "clean"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "mvqU7_mhU2Oi",
        "outputId": "eb04eae4-3366-45b8-b476-9d35963b3a1d"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                  Company  Reporting_Date  \\\n",
              "0                    Meta            2021   \n",
              "1                    Meta            2020   \n",
              "2                    Meta            2019   \n",
              "3                    Meta            2018   \n",
              "4                    Meta            2017   \n",
              "5             Merck & Co.            2021   \n",
              "6             Merck & Co.            2020   \n",
              "7             Merck & Co.            2019   \n",
              "8             Merck & Co.            2018   \n",
              "9             Merck & Co.            2017   \n",
              "10          Alphabet Inc.            2021   \n",
              "11          Alphabet Inc.            2020   \n",
              "12          Alphabet Inc.            2019   \n",
              "13          Alphabet Inc.            2018   \n",
              "14  Microsoft Corporation            2021   \n",
              "15  Microsoft Corporation            2020   \n",
              "16  Microsoft Corporation            2019   \n",
              "17  Microsoft Corporation            2018   \n",
              "18  Microsoft Corporation            2017   \n",
              "19                 Costco            2021   \n",
              "20                 Costco            2020   \n",
              "21                 Costco            2019   \n",
              "22                 Costco            2018   \n",
              "23                 Costco            2017   \n",
              "24                 Pfizer            2021   \n",
              "25                 Pfizer            2020   \n",
              "26                 Pfizer            2019   \n",
              "27                 Pfizer            2018   \n",
              "28                 Pfizer            2017   \n",
              "29                PepsiCo            2021   \n",
              "30                PepsiCo            2020   \n",
              "31                PepsiCo            2019   \n",
              "32                PepsiCo            2018   \n",
              "33                PepsiCo            2017   \n",
              "34                 AbbVie            2021   \n",
              "35                 AbbVie            2020   \n",
              "36                 AbbVie            2019   \n",
              "37                 AbbVie            2018   \n",
              "38                 AbbVie            2017   \n",
              "39              Coca-Cola            2021   \n",
              "40              Coca-Cola            2020   \n",
              "41              Coca-Cola            2019   \n",
              "42              Coca-Cola            2018   \n",
              "43              Coca-Cola            2017   \n",
              "44             Mastercard            2021   \n",
              "45             Mastercard            2020   \n",
              "46             Mastercard            2019   \n",
              "47             Mastercard            2018   \n",
              "48             Mastercard            2017   \n",
              "\n",
              "                                                    1  \\\n",
              "0   . We had a global workforce of 71,970 employee...   \n",
              "1   . Facebook Reality Labs' augmented and virtual...   \n",
              "2   . We also help people discover and learn about...   \n",
              "3   . The GDPR includes operational requirements f...   \n",
              "4   . We work directly with these advertisers, thr...   \n",
              "5   . The highly competitive animal health busines...   \n",
              "6   Research and Development Update The Company cu...   \n",
              "7   . Competitive pressures have intensified as pr...   \n",
              "8   . Competitive pressures have intensified as pr...   \n",
              "9   . Competitive pressures have intensified as pr...   \n",
              "10  . As of December 31, 2021, Alphabet had 156,50...   \n",
              "11  . We face formidable competition in every aspe...   \n",
              "12  . We face formidable competition in every aspe...   \n",
              "13   Brand advertising helps enhance users' awaren...   \n",
              "14  Investing in the Future Our success is based o...   \n",
              "15  Investing in the Future Our success is based o...   \n",
              "16  Mr. Nadella also serves on the Board of Direct...   \n",
              "17  This segment primarily comprises: Server produ...   \n",
              "18  This segment primarily comprises: Server produ...   \n",
              "19  Mr. Klauer was Senior Vice President, Non-Food...   \n",
              "20  Net sales for e-commerce represented approxima...   \n",
              "21  Our annual fee for these memberships is $60 in...   \n",
              "22  Our annual fee for these memberships is $60 in...   \n",
              "23  The Executive membership fee increased from $1...   \n",
              "24  . Governments globally may use a variety of me...   \n",
              "25  . Information relating to corporate governance...   \n",
              "26  Information relating to corporate governance a...   \n",
              "27  As part of our business strategy, we are capit...   \n",
              "28  Note: Some amounts in this 2016 Form 10-K may ...   \n",
              "29  . We are also required to comply with the Fore...   \n",
              "30  . (Dole) and Ocean Spray Cranberries, Inc.. We...   \n",
              "31  . (Dole) and Ocean Spray Cranberries, Inc.. We...   \n",
              "32  . (Dole) and Ocean Spray Cranberries, Inc.. We...   \n",
              "33  These activities principally involve: developm...   \n",
              "34  AbbVies medical device products are subject to...   \n",
              "35  AbbVie's capital expenditures for pollution co...   \n",
              "36  Allergan markets a portfolio of brands and pro...   \n",
              "37  . Managed care providers (for example, health ...   \n",
              "38  .  VENCLEXTA (venetoclax) is approved to treat...   \n",
              "39  These include companies that, like our Company...   \n",
              "40  These include companies that, like our Company...   \n",
              "41  We are also subject to various federal, state ...   \n",
              "42  . In addition, certain U.S. bottlers that were...   \n",
              "43  . In addition, certain U.S. bottlers that were...   \n",
              "44  . Financial and other material information is ...   \n",
              "45  Financial and other material information is ro...   \n",
              "46                           Business      .  Item 1.   \n",
              "47  . Financial and other material information is ...   \n",
              "48  . Financial and other material information is ...   \n",
              "\n",
              "                                                   1A  \\\n",
              "0   . In the United States, there have been, and c...   \n",
              "1   . At our scale, it is very difficult to attrib...   \n",
              "2   . At our scale, it is very difficult to attrib...   \n",
              "3   . We are subject to a variety of laws and regu...   \n",
              "4   . We are subject to a variety of laws and regu...   \n",
              "5   .  Changes in government laws and regulations,...   \n",
              "6   . As a result of the Companys dependence on ke...   \n",
              "7   . As a result of the Companys dependence on ke...   \n",
              "8   In addition, the network cyber-attack experien...   \n",
              "9   In addition, the network cyber-attack experien...   \n",
              "10  . Any increase in the unauthorized use of our ...   \n",
              "11  . Any increase in the unauthorized use of our ...   \n",
              "12  . Any increase in the unauthorized use of our ...   \n",
              "13  . Any increase in the unauthorized use of our ...   \n",
              "14  In addition, economic and political pressures ...   \n",
              "15  In addition, economic and political pressures ...   \n",
              "16  We will continue to make significant investmen...   \n",
              "17  In addition, economic and political pressures ...   \n",
              "18  In addition, economic and political pressures ...   \n",
              "19  The retail business is highly competitive.. . ...   \n",
              "20  The retail business is highly competitive.. . ...   \n",
              "21  The retail business is highly competitive.. . ...   \n",
              "22  The retail business is highly competitive.. . ...   \n",
              "23  The retail business is highly competitive.. . ...   \n",
              "24  We produce, collect, process, store and transm...   \n",
              "25  For IPRD assets, the risk of failure is signif...   \n",
              "26  For IPRD assets, the risk of failure is signif...   \n",
              "27  For IPRD assets, the risk of failure is signif...   \n",
              "28  For IPRD assets, the risk of failure is signif...   \n",
              "29  Many of our employees are covered by collectiv...   \n",
              "30  Many of our employees are covered by collectiv...   \n",
              "31  Many of these laws and regulations have differ...   \n",
              "32  Many of these laws and regulations have differ...   \n",
              "33  Many of these laws and regulations have differ...   \n",
              "34  . The manufacture of many of AbbVie's products...   \n",
              "35  . The manufacture of many of AbbVie's products...   \n",
              "36  . AbbVie also intends to assume all the existi...   \n",
              "37  .  Biologics carry unique risks and uncertaint...   \n",
              "38  . The potential for continuing 14    |  2017 F...   \n",
              "39  In the conduct of our business, we rely on rel...   \n",
              "40  In the conduct of our business, we rely on rel...   \n",
              "41  In the conduct of our business, we rely on rel...   \n",
              "42  In the conduct of our business, we rely on rel...   \n",
              "43  The final amounts may be significantly affecte...   \n",
              "44  As cyber-threats continue to evolve, we may be...   \n",
              "45  As cyber-threats continue to evolve, we may be...   \n",
              "46                       Item 1A.. Risk factors         \n",
              "47  As cyber-threats continue to evolve, we may be...   \n",
              "48  As cyber-threats continue to evolve, we may be...   \n",
              "\n",
              "                                                   1B  \\\n",
              "0        .  Item 1B.. Unresolved Staff Comments None.   \n",
              "1        .  Item 1B.. Unresolved Staff Comments None.   \n",
              "2        .  Item 1B.. Unresolved Staff Comments None.   \n",
              "3        .  Item 1B.. Unresolved Staff Comments None.   \n",
              "4        .  Item 1B.. Unresolved Staff Comments None.   \n",
              "5      .  Item 1B.. Unresolved Staff Comments.. None.   \n",
              "6      .  Item 1B.. Unresolved Staff Comments.. None.   \n",
              "7      .  Item 1B.. Unresolved Staff Comments.. None.   \n",
              "8      .  Item 1B.. Unresolved Staff Comments.. None.   \n",
              "9      .  Item 1B.. Unresolved Staff Comments.. None.   \n",
              "10  . UNRESOLVED STAFF COMMENTS Not applicable..  ...   \n",
              "11  . UNRESOLVED STAFF COMMENTS Not applicable.. A...   \n",
              "12  . UNRESOLVED STAFF COMMENTS Not applicable..  ...   \n",
              "13  . UNRESOLVED STAFF COMMENTS Not applicable..  ...   \n",
              "14  . UNRESOLVED STAFF COMMENTS We have received n...   \n",
              "15  UNRESOLVED STAFF COMMENTS We have received no ...   \n",
              "16  . UNRESOLVED STAFF COMMENTS We have received n...   \n",
              "17  .  ITEM 1B.. UNRESOLVE D STAFF COMMENTS We hav...   \n",
              "18  .  ITEM 1B.. UNRESOLVE D STAFF COMMENTS We hav...   \n",
              "19          .  Item 1BUnresolved Staff Comments None.   \n",
              "20          .  Item 1BUnresolved Staff Comments None.   \n",
              "21          .  Item 1BUnresolved Staff Comments None.   \n",
              "22          .  Item 1BUnresolved Staff Comments None.   \n",
              "23          .  Item 1BUnresolved Staff Comments None.   \n",
              "24  We produce, collect, process, store and transm...   \n",
              "25  For IPRD assets, the risk of failure is signif...   \n",
              "26  . UNRESOLVED STAFF COMMENTS Not applicable..  ...   \n",
              "27  . UNRESOLVED STAFF COMMENTS Not applicable..  ...   \n",
              "28  . UNRESOLVED STAFF COMMENTS Not applicable..  ...   \n",
              "29  Table of Contents . We have received no writte...   \n",
              "30  Table of Contents .  Item 1B.. Unresolved Staf...   \n",
              "31  . We have received no written comments regardi...   \n",
              "32  .  Item 1B.. Unresolved Staff Comments.. We ha...   \n",
              "33  .  Item 1B.. Unresolved Staff Comments.. We ha...   \n",
              "34       .  ITEM 1B.. UNRESOLVED STAFF COMMENTS None.   \n",
              "35       .  ITEM 1B.. UNRESOLVED STAFF COMMENTS None.   \n",
              "36      . UNRESOLVED STAFF COMMENTS  None..  ITEM 1B.   \n",
              "37      . UNRESOLVED STAFF COMMENTS  None..  ITEM 1B.   \n",
              "38      . UNRESOLVED STAFF COMMENTS  None..  ITEM 1B.   \n",
              "39  . UNRESOLVED STAFF COMMENTS Not applicable..  ...   \n",
              "40  . UNRESOLVED STAFF COMMENTS Not applicable..  ...   \n",
              "41  . UNRESOLVED STAFF COMMENTS Not applicable..  ...   \n",
              "42  . UNRESOLVED STAFF COMMENTS Not applicable..  ...   \n",
              "43  . UNRESOLVED STAFF COMMENTS Not applicable..  ...   \n",
              "44  .  Item 1B.. Unresolved staff comments Not app...   \n",
              "45  .  Item 1B.. Unresolved staff comments Not app...   \n",
              "46         Unresolved staff comments      .  Item 1B.   \n",
              "47  . UNRESOLVED STAFF COMMENTS Not applicable..  ...   \n",
              "48  . UNRESOLVED STAFF COMMENTS Not applicable..  ...   \n",
              "\n",
              "                                                    2  \\\n",
              "0   .  Item 2.. As of December 31, 2021, we owned ...   \n",
              "1   . In addition, we have offices in more than 80...   \n",
              "2   .  Item 2.. We also own 15 data centers global...   \n",
              "3   .  Item 2.. As of December 31, 2018 , we owned...   \n",
              "4   .  Item 2.. As such, we have excluded the squa...   \n",
              "5   .  Item 2.. Mercks manufacturing operations ar...   \n",
              "6   A number of properties will be transferred to ...   \n",
              "7   .  Item 2.. The Companys corporate headquarter...   \n",
              "8   . Abroad, such expenditures amounted to $1.1 b...   \n",
              "9   .  Item 2.. The Companys corporate headquarter...   \n",
              "10  We believe our existing facilities, both owned...   \n",
              "11  We believe our existing facilities, both owned...   \n",
              "12  We believe our existing facilities, both owned...   \n",
              "13  We believe our existing facilities, both owned...   \n",
              "14  The largest leased properties include space in...   \n",
              "15  These facilities include approximately 10 mill...   \n",
              "16  In addition, we own and lease space domestical...   \n",
              "17  In addition, we own and lease space domestical...   \n",
              "18  In addition, we own and lease space domestical...   \n",
              "19  . Total square feet associated with distributi...   \n",
              "20  . Total square feet associated with distributi...   \n",
              "21  . Our executive offices are located in Issaqua...   \n",
              "22  .  Item 2Properties Warehouse Properties At Se...   \n",
              "23  . We operate 24 depots, consisting of approxim...   \n",
              "24  . We continue to advance our global workplace ...   \n",
              "25  . We expect to relocate our global headquarter...   \n",
              "26  Pfizer continues to own and lease space around...   \n",
              "27  Pfizer continues to own and lease space around...   \n",
              "28  Pfizer continues to own and lease space around...   \n",
              "29  . See Note 13 to our consolidated financial st...   \n",
              "30  . Our principal executive office located in Pu...   \n",
              "31  . Our principal executive office located in Pu...   \n",
              "32   Shared service centers in Winston-Salem, Nort...   \n",
              "33  .  Item 2.. We believe that our properties gen...   \n",
              "34  AbbVie believes its facilities are suitable an...   \n",
              "35  In addition to the above, AbbVie has other man...   \n",
              "36  . PROPERTIES  AbbVie's corporate offices are l...   \n",
              "37  PROPERTIES  AbbVie's corporate offices are loc...   \n",
              "38  PROPERTIES  AbbVie's corporate offices are loc...   \n",
              "39  . However, management believes that additional...   \n",
              "40  . The office complex also includes several oth...   \n",
              "41  . However, management believes that additional...   \n",
              "42  . We also own an office and retail building at...   \n",
              "43  . We also own an office and retail building at...   \n",
              "44  Properties We own our corporate headquarters, ...   \n",
              "45  Properties We own our corporate headquarters, ...   \n",
              "46                          Item 2.. Properties         \n",
              "47  . These facilities primarily consist of corpor...   \n",
              "48  . Our leased properties in the United States a...   \n",
              "\n",
              "                                                    3  \\\n",
              "0   In addition, our platform and user data practi...   \n",
              "1   In addition, our platform and user data practi...   \n",
              "2   In addition, our platform and user data practi...   \n",
              "3   . We believe these lawsuits are without merit,...   \n",
              "4   . We believe we have multiple legal grounds to...   \n",
              "5   The information called for by this Item is inc...   \n",
              "6   The information called for by this Item is inc...   \n",
              "7   The information called for by this Item is inc...   \n",
              "8   The information called for by this Item is inc...   \n",
              "9   The information called for by this Item is inc...   \n",
              "10  . LEGAL PROCEEDINGS For a description of our m...   \n",
              "11  . LEGAL PROCEEDINGS For a description of our m...   \n",
              "12  . LEGAL PROCEEDINGS For a description of our m...   \n",
              "13  LEGAL PROCEEDINGS For a description of our mat...   \n",
              "14  . LEGAL PROCEEDINGS Refer to Note 15  Continge...   \n",
              "15  . Ballmer et al, United States District Court ...   \n",
              "16  . LEGAL PROCEEDINGS While not material to the ...   \n",
              "17  . LEGAL PROCEEDINGS While not material to the ...   \n",
              "18  . LEGAL PROCEEDINGS While not material to the ...   \n",
              "19  .  Item 3Legal Proceedings See discussion of L...   \n",
              "20  .  Item 3Legal Proceedings See discussion of L...   \n",
              "21  .  Item 3Legal Proceedings See discussion of L...   \n",
              "22  .  Item 3Legal Proceedings See discussion of L...   \n",
              "23  .  Item 3Legal Proceedings See discussion of L...   \n",
              "24  Director of Zoetis Inc.. Group President, Pfiz...   \n",
              "25  and the National Health Council.. Director of ...   \n",
              "26  . LEGAL PROCEEDINGS Certain legal proceedings ...   \n",
              "27  . LEGAL PROCEEDINGS Certain legal proceedings ...   \n",
              "28  . LEGAL PROCEEDINGS Certain legal proceedings ...   \n",
              "29  Table of Contents . Legal Proceedings.. Busine...   \n",
              "30  . Legal Proceedings.. Business  Regulatory Mat...   \n",
              "31  . Legal Proceedings.. Business  Regulatory Mat...   \n",
              "32  . If the environmental authority determines PA...   \n",
              "33  . Legal Proceedings.. In October 2017, the Sup...   \n",
              "34  . LEGAL PROCEEDINGS Information pertaining to ...   \n",
              "35  . LEGAL PROCEEDINGS Information pertaining to ...   \n",
              "36  . LEGAL PROCEEDINGS  Information pertaining to...   \n",
              "37  .  ITEM 3.. LEGAL PROCEEDINGS  Information per...   \n",
              "38  .  ITEM 3.. LEGAL PROCEEDINGS  Information per...   \n",
              "39  . On January 23, 2013, the Chartis insurers fi...   \n",
              "40  . Some or all of this amount would be refunded...   \n",
              "41  . This decision effectively reduced the IRS' p...   \n",
              "42  . The Wisconsin Case initially was stayed, pen...   \n",
              "43  . The Wisconsin Case initially was stayed, pen...   \n",
              "44  .  Item 3.. Legal proceedings Refer to Note 13...   \n",
              "45  .  Item 3.. Legal proceedings Refer to Note 13...   \n",
              "46                  Legal proceedings      .  Item 3.   \n",
              "47  . LEGAL PROCEEDINGS Refer to Note 12 (Accrued ...   \n",
              "48  . LEGAL PROCEEDINGS Refer to Notes 10 (Accrued...   \n",
              "\n",
              "                                                    5  \\\n",
              "0   . The following graph shows a comparison of th...   \n",
              "1   . The stock price performance of the following...   \n",
              "2   . As of December 31, 2019 , there were 39 stoc...   \n",
              "3   . In December 2018, our board of directors aut...   \n",
              "4   . Purchases of Equity Securities by the Issuer...   \n",
              "5   The principal market for trading of the Compan...   \n",
              "6   The principal market for trading of the Compan...   \n",
              "7   . As of January 31, 2020, there were approxima...   \n",
              "8   . The principal market for trading of the Comp...   \n",
              "9   Issuer purchases of equity securities for the ...   \n",
              "10  Our Class C capital stock has been listed on t...   \n",
              "11  Our Class C capital stock has been listed on t...   \n",
              "12  Our Class C capital stock has been listed on t...   \n",
              "13  Our Class C capital stock has been listed on t...   \n",
              "14  Our share repurchases may occur through open m...   \n",
              "15  The above table excludes shares repurchased to...   \n",
              "16  MARKET FOR REGISTRANTS COMMON EQUITY, RELATED ...   \n",
              "17  The above table excludes shares repurchased to...   \n",
              "18  The above table excludes shares repurchased to...   \n",
              "19   Item 5Market for Registrants Common Equity, R...   \n",
              "20  .  Item 5Market for Registrants Common Equity,...   \n",
              "21  .  Item 5Market for Registrants Common Equity,...   \n",
              "22  .  Item 5Market for Registrants Common Equity,...   \n",
              "23  .  Item 5Market for Registrants Common Equity,...   \n",
              "24  The following summarizes purchases of our comm...   \n",
              "25  2020 Form 10-K . As of February 23, 2021, ther...   \n",
              "26  (b)  These columns represent (i) 108,367 share...   \n",
              "27  . Additional information required by this item...   \n",
              "28  . On June 20, 2016, the accelerated share repu...   \n",
              "29  For the remainder of 2022, the record dates fo...   \n",
              "30  On February 4, 2021, the Board of Directors de...   \n",
              "31  . Issuer Purchases of Common Stock Period Tota...   \n",
              "32  Such shares may be repurchased in open market ...   \n",
              "33  Such shares may be repurchased in open market ...   \n",
              "34  In addition to AbbVie shares repurchased on th...   \n",
              "35  . In addition to AbbVie shares repurchased on ...   \n",
              "36  Performance Graph The following graph compares...   \n",
              "37  Dividends On November 2, 2018 , AbbVie's board...   \n",
              "38  Moreover, if AbbVie determines to pay any divi...   \n",
              "39  As of February 18, 2022, there were 191,391 sh...   \n",
              "40  This column discloses the number of shares ava...   \n",
              "41  . In 2019, the Dow Jones Food  Beverage Index ...   \n",
              "42  . and US Foods Holding Corp.. MARKET FOR REGIS...   \n",
              "43  This column discloses the number of shares pur...   \n",
              "44  . Mastercards Class B common stock is not publ...   \n",
              "45  Mastercards Class B common stock is not public...   \n",
              "46  Mastercards Class B common stock is not public...   \n",
              "47  . Mastercards Class B common stock is not publ...   \n",
              "48  . This program will become effective after com...   \n",
              "\n",
              "                                                    7  \\\n",
              "0   . At our scale, it is very difficult to attrib...   \n",
              "1   . At our scale, it is very difficult to attrib...   \n",
              "2   . At our scale, it is very difficult to attrib...   \n",
              "3   Revenue in 2017 increased $13.02 billion, or 4...   \n",
              "4   . General and administrative.. Although we bel...   \n",
              "5   For details on the components of Other (income...   \n",
              "6   Impairments of Long-Lived Assets The Company a...   \n",
              "7   In February 2020, Merck confirmed that four Af...   \n",
              "8   Impairments of Long-Lived Assets The Company a...   \n",
              "9   The Company recorded an aggregate charge of $2...   \n",
              "10  A number of Other Bets initiatives are in thei...   \n",
              "11  . The time frame from date of purchase to plac...   \n",
              "12  .  Our employees are critical to our success a...   \n",
              "13  For example, we have seen an increase in YouTu...   \n",
              "14  These provisions require us to capitalize rese...   \n",
              "15  The fair value of each reporting unit is estim...   \n",
              "16  The fair value of each reporting unit is estim...   \n",
              "17  Enterprise Services revenue increased $304 mil...   \n",
              "18  Enterprise Services revenue increased $304 mil...   \n",
              "19  . The increase was across all categories, most...   \n",
              "20  . In April 2020, the Board of Directors increa...   \n",
              "21  . Sales comparisons can also be particularly i...   \n",
              "22  Our primary requirement for capital is acquiri...   \n",
              "23  . Our Executive members qualify for a 2% rewar...   \n",
              "24  . The operational increase in emerging markets...   \n",
              "25  At December 31, 2020, our remaining share-purc...   \n",
              "26  .  ITEM 7.. MANAGEMENTS DISCUSSION AND ANALYSI...   \n",
              "27  .  ITEM 7.. MANAGEMENTS DISCUSSION AND ANALYSI...   \n",
              "28   ITEM 7.. Pfizer Inc.. MANAGEMENTS DISCUSSION ...   \n",
              "29  The commingled funds are based on the publishe...   \n",
              "30  The allocation methodology is based on our for...   \n",
              "31  The carrying value of indefinite-lived intangi...   \n",
              "32  . The allocation methodology is based on our f...   \n",
              "33  . The allocation methodology is based on our f...   \n",
              "34  Valuation of Goodwill and Intangible Assets Ab...   \n",
              "35  Valuation of Goodwill and Intangible Assets Ab...   \n",
              "36  This action does not impact any of the approve...   \n",
              "37  IPRD acquired in transactions that are not bus...   \n",
              "38  The increase in the effective tax rate for 201...   \n",
              "39  . In the fourth quarter of 2020, the Company s...   \n",
              "40  Refer to the heading \"Beverage Volume\" below.....   \n",
              "41  Refer to the heading \"Beverage Volume\" below.....   \n",
              "42  Refer to the heading \"Beverage Volume\" below.....   \n",
              "43  Refer to the heading \"Beverage Volume\" below.....   \n",
              "44  Managements discussion and analysis of financi...   \n",
              "45  . Managements discussion and analysis of finan...   \n",
              "46  This    includes 2 percentage points of growth...   \n",
              "47  . 2 Represents the foreign currency translatio...   \n",
              "48  . The following tables reconcile our as-report...   \n",
              "\n",
              "                                                   7A  \\\n",
              "0   . Equity investments accounted for under the e...   \n",
              "1   . Foreign currency losses of $129 million, $10...   \n",
              "2   . Quantitative and Qualitative Disclosures Abo...   \n",
              "3   We have experienced and will continue to exper...   \n",
              "4   We have experienced and will continue to exper...   \n",
              "5    Item 7A.. Managements Discussion and Analysis...   \n",
              "6    Item 7A.. Managements Discussion and Analysis...   \n",
              "7   .  Item 7A.. Managements Discussion and Analys...   \n",
              "8   .  Item 7A.. Managements Discussion and Analys...   \n",
              "9   .  Item 7A.. Managements Discussion and Analys...   \n",
              "10  . foreign currency exchange rates and determin...   \n",
              "11  . The change in the value recorded in AOCI wou...   \n",
              "12  . If the U.S. dollar weakened by 10%, the amou...   \n",
              "13  . The change in the value recorded in AOCI wou...   \n",
              "14  SENSITIVITY ANALYSIS The following table sets ...   \n",
              "15  Equity Securities held in our equity investmen...   \n",
              "16  Equity Securities held in our equity investmen...   \n",
              "17  SENSITIVITY ANALYSIS The following table sets ...   \n",
              "18  SENSITIVITY ANALYSIS The following table sets ...   \n",
              "19  Fluctuations in interest rates may affect the ...   \n",
              "20  Fluctuations in interest rates may affect the ...   \n",
              "21  Fluctuations in interest rates may affect the ...   \n",
              "22  Fluctuations in interest rates may affect the ...   \n",
              "23  Fluctuations in interest rates may affect the ...   \n",
              "24   ITEM 7A.. Pfizer Inc.. 2021 Form 10-K . QUANT...   \n",
              "25   ITEM 7A.. Pfizer Inc.. 2020 Form 10-K . QUANT...   \n",
              "26  2019 Form 10-K We borrow primarily on a long-t...   \n",
              "27  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT...   \n",
              "28  .  ITEM 7A.. QUANTITATIVE AND QUALITATIVE DISC...   \n",
              "29  Included in Item 7.. .  Item 7A.. Managements ...   \n",
              "30  Included in Item 7.. .  Item 7A.. Managements ...   \n",
              "31  Included in Item 7.. .  Item 7A.. Managements ...   \n",
              "32  Included in Item 7.. .  Item 7A.. Managements ...   \n",
              "33  Included in Item 7.. .  Item 7A.. Managements ...   \n",
              "34  Certain derivative instruments are used when a...   \n",
              "35  As a result, any foreign currency translation ...   \n",
              "36  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT...   \n",
              "37  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT...   \n",
              "38  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT...   \n",
              "39  . We use derivative financial instruments to f...   \n",
              "40  . These values include derivative instruments ...   \n",
              "41  . These values include derivative instruments ...   \n",
              "42  . These values include derivative instruments ...   \n",
              "43  . These values include derivative instruments ...   \n",
              "44  Management monitors risk exposures on an ongoi...   \n",
              "45  The Company did not have any outstanding short...   \n",
              "46  To manage this risk, we enter into foreign exc...   \n",
              "47  . The fair value and maturity distribution of ...   \n",
              "48  . The effect of a hypothetical 10% adverse cha...   \n",
              "\n",
              "                                                    8  \\\n",
              "0   . In October 2021, we changed our corporate na...   \n",
              "1   . We have agreed to hold certain parties harml...   \n",
              "2   . The aggregate intrinsic value of the options...   \n",
              "3   . See Note 12 in these notes to the consolidat...   \n",
              "4   . See Note 12 in these notes to the consolidat...   \n",
              "5   The amount ultimately reclassified to Sales ma...   \n",
              "6   In our opinion, the consolidated financial sta...   \n",
              "7   The Company recorded an aggregate charge of $ ...   \n",
              "8   . The amount ultimately reclassified to Sales ...   \n",
              "9   . Capitalized software costs associated with p...   \n",
              "10  . As described in Note 10 to the consolidated ...   \n",
              "11  . For non-marketable equity securities we cons...   \n",
              "12  . Google generates revenues primarily from adv...   \n",
              "13  . Nature of Operations and Summary of Signific...   \n",
              "14  Our products are generally sold with a right o...   \n",
              "15  We applied a modified retrospective approach t...   \n",
              "16  We adopted the standard effective July 1, 2019...   \n",
              "17  Option and forward contracts are used to hedge...   \n",
              "18  Option and forward contracts are used to hedge...   \n",
              "19  These contracts meet the characteristics of de...   \n",
              "20  . These contracts meet the characteristics of ...   \n",
              "21  The components of the deferred tax assets (lia...   \n",
              "22  . Maturities of long-term debt during the next...   \n",
              "23  .  Item 8Financial Statements and Supplementar...   \n",
              "24  . In addition, the direct purchaser class plai...   \n",
              "25  . In addition, the direct purchaser class plai...   \n",
              "26  . FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA ...   \n",
              "27  . FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA ...   \n",
              "28  . FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA ...   \n",
              "29   Item 8.. . Financial Statements and Supplemen...   \n",
              "30  . Other Information.. Except as discussed, the...   \n",
              "31   Item 8.. . Financial Statements and Supplemen...   \n",
              "32   Item 8.. . Financial Statements and Supplemen...   \n",
              "33   Item 8.. . Financial Statements and Supplemen...   \n",
              "34  In October 2021, the May 2021 declaratory judg...   \n",
              "35  The following table summarizes benefit plan in...   \n",
              "36  Allergan markets a portfolio of brands and pro...   \n",
              "37    2018 Form 10-K  |   53 Recent Accounting Pro...   \n",
              "38  The effective income tax rate in 2016 included...   \n",
              "39  This includes certain pricing models, discount...   \n",
              "40  This includes certain pricing models, discount...   \n",
              "41  . This difference is not amortized.. Refer to ...   \n",
              "42  . This difference is not amortized.. 2  Expect...   \n",
              "43  . This difference is not amortized.. 2  Expect...   \n",
              "44  The remaining RSUs will be settled in shares o...   \n",
              "45  In our opinion, the consolidated financial sta...   \n",
              "46  The remaining RSUs will be settled in shares o...   \n",
              "47  . In February 2013, the district court granted...   \n",
              "48  As of December 31, 2017 , Mastercard had accru...   \n",
              "\n",
              "                                                   9A  \n",
              "0   Limitations on Effectiveness of Controls and P...  \n",
              "1   Limitations on Effectiveness of Controls and P...  \n",
              "2   Limitations on Effectiveness of Controls and P...  \n",
              "3   Limitations on Effectiveness of Controls and P...  \n",
              "4   Limitations on Effectiveness of Controls and P...  \n",
              "5   These statements are prepared in conformity wi...  \n",
              "6   These statements are prepared in conformity wi...  \n",
              "7   These statements are prepared in conformity wi...  \n",
              "8   These statements are prepared in conformity wi...  \n",
              "9   These statements are prepared in conformity wi...  \n",
              "10  . Based on this evaluation, our chief executiv...  \n",
              "11  . While pre-existing controls were not specifi...  \n",
              "12  . The ERP system is designed to accurately mai...  \n",
              "13  . The effectiveness of our internal control ov...  \n",
              "14  Also, projections of any evaluation of effecti...  \n",
              "15  We are a public accounting firm registered wit...  \n",
              "16  We are a public accounting firm registered wit...  \n",
              "17  We are a public accounting firm registered wit...  \n",
              "18  We are a public accounting firm registered wit...  \n",
              "19  Based on its assessment, management has conclu...  \n",
              "20  Based on its assessment, management has conclu...  \n",
              "21  During 2019 , management implemented our previ...  \n",
              "22  We expect that the remediation of this materia...  \n",
              "23   Item 9AControls and Procedures Disclosure Con...  \n",
              "24  2021 Form 10-K PART III . 2021 Form 10-K Repor...  \n",
              "25  Management assessed the effectiveness of the C...  \n",
              "26  . Internal Control over Financial Reporting Ma...  \n",
              "27  .  ITEM 9A.. Based on this evaluation, our pri...  \n",
              "28  . CONTROLS AND PROCEDURES Disclosure Controls ...  \n",
              "29  . Beginning in the fourth quarter of 2021 and ...  \n",
              "30  . Except as discussed, there have been no chan...  \n",
              "31  . In addition, in connection with our 2019 mul...  \n",
              "32  . Except as discussed, there have been no chan...  \n",
              "33  . Based on that evaluation, our management con...  \n",
              "34  Based on that assessment, management concluded...  \n",
              "35  There were no changes in AbbVie's internal con...  \n",
              "36  The report of AbbVie's independent registered ...  \n",
              "37    2018 Form 10-K  |   89 Report of independent...  \n",
              "38  /s/ Ernst  Young LLP Chicago, Illinois Februar...  \n",
              "39  . CONTROLS AND PROCEDURES Evaluation of Disclo...  \n",
              "40  . Changes in Internal Control Over Financial R...  \n",
              "41  Changes in Internal Control Over Financial Rep...  \n",
              "42  Report of Management on Internal Control Over ...  \n",
              "43  . Management has excluded from the scope of it...  \n",
              "44  . PricewaterhouseCoopers LLP, an independent r...  \n",
              "45  . PricewaterhouseCoopers LLP, an independent r...  \n",
              "46  . Changes in Internal Control over Financial R...  \n",
              "47  . PricewaterhouseCoopers LLP, an independent r...  \n",
              "48  The President and Chief Executive Officer and ...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-ce7f6355-1878-4631-8781-f8d0d55eb624\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Company</th>\n",
              "      <th>Reporting_Date</th>\n",
              "      <th>1</th>\n",
              "      <th>1A</th>\n",
              "      <th>1B</th>\n",
              "      <th>2</th>\n",
              "      <th>3</th>\n",
              "      <th>5</th>\n",
              "      <th>7</th>\n",
              "      <th>7A</th>\n",
              "      <th>8</th>\n",
              "      <th>9A</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2021</td>\n",
              "      <td>. We had a global workforce of 71,970 employee...</td>\n",
              "      <td>. In the United States, there have been, and c...</td>\n",
              "      <td>.  Item 1B.. Unresolved Staff Comments None.</td>\n",
              "      <td>.  Item 2.. As of December 31, 2021, we owned ...</td>\n",
              "      <td>In addition, our platform and user data practi...</td>\n",
              "      <td>. The following graph shows a comparison of th...</td>\n",
              "      <td>. At our scale, it is very difficult to attrib...</td>\n",
              "      <td>. Equity investments accounted for under the e...</td>\n",
              "      <td>. In October 2021, we changed our corporate na...</td>\n",
              "      <td>Limitations on Effectiveness of Controls and P...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2020</td>\n",
              "      <td>. Facebook Reality Labs' augmented and virtual...</td>\n",
              "      <td>. At our scale, it is very difficult to attrib...</td>\n",
              "      <td>.  Item 1B.. Unresolved Staff Comments None.</td>\n",
              "      <td>. In addition, we have offices in more than 80...</td>\n",
              "      <td>In addition, our platform and user data practi...</td>\n",
              "      <td>. The stock price performance of the following...</td>\n",
              "      <td>. At our scale, it is very difficult to attrib...</td>\n",
              "      <td>. Foreign currency losses of $129 million, $10...</td>\n",
              "      <td>. We have agreed to hold certain parties harml...</td>\n",
              "      <td>Limitations on Effectiveness of Controls and P...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2019</td>\n",
              "      <td>. We also help people discover and learn about...</td>\n",
              "      <td>. At our scale, it is very difficult to attrib...</td>\n",
              "      <td>.  Item 1B.. Unresolved Staff Comments None.</td>\n",
              "      <td>.  Item 2.. We also own 15 data centers global...</td>\n",
              "      <td>In addition, our platform and user data practi...</td>\n",
              "      <td>. As of December 31, 2019 , there were 39 stoc...</td>\n",
              "      <td>. At our scale, it is very difficult to attrib...</td>\n",
              "      <td>. Quantitative and Qualitative Disclosures Abo...</td>\n",
              "      <td>. The aggregate intrinsic value of the options...</td>\n",
              "      <td>Limitations on Effectiveness of Controls and P...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2018</td>\n",
              "      <td>. The GDPR includes operational requirements f...</td>\n",
              "      <td>. We are subject to a variety of laws and regu...</td>\n",
              "      <td>.  Item 1B.. Unresolved Staff Comments None.</td>\n",
              "      <td>.  Item 2.. As of December 31, 2018 , we owned...</td>\n",
              "      <td>. We believe these lawsuits are without merit,...</td>\n",
              "      <td>. In December 2018, our board of directors aut...</td>\n",
              "      <td>Revenue in 2017 increased $13.02 billion, or 4...</td>\n",
              "      <td>We have experienced and will continue to exper...</td>\n",
              "      <td>. See Note 12 in these notes to the consolidat...</td>\n",
              "      <td>Limitations on Effectiveness of Controls and P...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2017</td>\n",
              "      <td>. We work directly with these advertisers, thr...</td>\n",
              "      <td>. We are subject to a variety of laws and regu...</td>\n",
              "      <td>.  Item 1B.. Unresolved Staff Comments None.</td>\n",
              "      <td>.  Item 2.. As such, we have excluded the squa...</td>\n",
              "      <td>. We believe we have multiple legal grounds to...</td>\n",
              "      <td>. Purchases of Equity Securities by the Issuer...</td>\n",
              "      <td>. General and administrative.. Although we bel...</td>\n",
              "      <td>We have experienced and will continue to exper...</td>\n",
              "      <td>. See Note 12 in these notes to the consolidat...</td>\n",
              "      <td>Limitations on Effectiveness of Controls and P...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>Merck &amp; Co.</td>\n",
              "      <td>2021</td>\n",
              "      <td>. The highly competitive animal health busines...</td>\n",
              "      <td>.  Changes in government laws and regulations,...</td>\n",
              "      <td>.  Item 1B.. Unresolved Staff Comments.. None.</td>\n",
              "      <td>.  Item 2.. Mercks manufacturing operations ar...</td>\n",
              "      <td>The information called for by this Item is inc...</td>\n",
              "      <td>The principal market for trading of the Compan...</td>\n",
              "      <td>For details on the components of Other (income...</td>\n",
              "      <td>Item 7A.. Managements Discussion and Analysis...</td>\n",
              "      <td>The amount ultimately reclassified to Sales ma...</td>\n",
              "      <td>These statements are prepared in conformity wi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>Merck &amp; Co.</td>\n",
              "      <td>2020</td>\n",
              "      <td>Research and Development Update The Company cu...</td>\n",
              "      <td>. As a result of the Companys dependence on ke...</td>\n",
              "      <td>.  Item 1B.. Unresolved Staff Comments.. None.</td>\n",
              "      <td>A number of properties will be transferred to ...</td>\n",
              "      <td>The information called for by this Item is inc...</td>\n",
              "      <td>The principal market for trading of the Compan...</td>\n",
              "      <td>Impairments of Long-Lived Assets The Company a...</td>\n",
              "      <td>Item 7A.. Managements Discussion and Analysis...</td>\n",
              "      <td>In our opinion, the consolidated financial sta...</td>\n",
              "      <td>These statements are prepared in conformity wi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>Merck &amp; Co.</td>\n",
              "      <td>2019</td>\n",
              "      <td>. Competitive pressures have intensified as pr...</td>\n",
              "      <td>. As a result of the Companys dependence on ke...</td>\n",
              "      <td>.  Item 1B.. Unresolved Staff Comments.. None.</td>\n",
              "      <td>.  Item 2.. The Companys corporate headquarter...</td>\n",
              "      <td>The information called for by this Item is inc...</td>\n",
              "      <td>. As of January 31, 2020, there were approxima...</td>\n",
              "      <td>In February 2020, Merck confirmed that four Af...</td>\n",
              "      <td>.  Item 7A.. Managements Discussion and Analys...</td>\n",
              "      <td>The Company recorded an aggregate charge of $ ...</td>\n",
              "      <td>These statements are prepared in conformity wi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>Merck &amp; Co.</td>\n",
              "      <td>2018</td>\n",
              "      <td>. Competitive pressures have intensified as pr...</td>\n",
              "      <td>In addition, the network cyber-attack experien...</td>\n",
              "      <td>.  Item 1B.. Unresolved Staff Comments.. None.</td>\n",
              "      <td>. Abroad, such expenditures amounted to $1.1 b...</td>\n",
              "      <td>The information called for by this Item is inc...</td>\n",
              "      <td>. The principal market for trading of the Comp...</td>\n",
              "      <td>Impairments of Long-Lived Assets The Company a...</td>\n",
              "      <td>.  Item 7A.. Managements Discussion and Analys...</td>\n",
              "      <td>. The amount ultimately reclassified to Sales ...</td>\n",
              "      <td>These statements are prepared in conformity wi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>Merck &amp; Co.</td>\n",
              "      <td>2017</td>\n",
              "      <td>. Competitive pressures have intensified as pr...</td>\n",
              "      <td>In addition, the network cyber-attack experien...</td>\n",
              "      <td>.  Item 1B.. Unresolved Staff Comments.. None.</td>\n",
              "      <td>.  Item 2.. The Companys corporate headquarter...</td>\n",
              "      <td>The information called for by this Item is inc...</td>\n",
              "      <td>Issuer purchases of equity securities for the ...</td>\n",
              "      <td>The Company recorded an aggregate charge of $2...</td>\n",
              "      <td>.  Item 7A.. Managements Discussion and Analys...</td>\n",
              "      <td>. Capitalized software costs associated with p...</td>\n",
              "      <td>These statements are prepared in conformity wi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>Alphabet Inc.</td>\n",
              "      <td>2021</td>\n",
              "      <td>. As of December 31, 2021, Alphabet had 156,50...</td>\n",
              "      <td>. Any increase in the unauthorized use of our ...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS Not applicable..  ...</td>\n",
              "      <td>We believe our existing facilities, both owned...</td>\n",
              "      <td>. LEGAL PROCEEDINGS For a description of our m...</td>\n",
              "      <td>Our Class C capital stock has been listed on t...</td>\n",
              "      <td>A number of Other Bets initiatives are in thei...</td>\n",
              "      <td>. foreign currency exchange rates and determin...</td>\n",
              "      <td>. As described in Note 10 to the consolidated ...</td>\n",
              "      <td>. Based on this evaluation, our chief executiv...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>Alphabet Inc.</td>\n",
              "      <td>2020</td>\n",
              "      <td>. We face formidable competition in every aspe...</td>\n",
              "      <td>. Any increase in the unauthorized use of our ...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS Not applicable.. A...</td>\n",
              "      <td>We believe our existing facilities, both owned...</td>\n",
              "      <td>. LEGAL PROCEEDINGS For a description of our m...</td>\n",
              "      <td>Our Class C capital stock has been listed on t...</td>\n",
              "      <td>. The time frame from date of purchase to plac...</td>\n",
              "      <td>. The change in the value recorded in AOCI wou...</td>\n",
              "      <td>. For non-marketable equity securities we cons...</td>\n",
              "      <td>. While pre-existing controls were not specifi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>Alphabet Inc.</td>\n",
              "      <td>2019</td>\n",
              "      <td>. We face formidable competition in every aspe...</td>\n",
              "      <td>. Any increase in the unauthorized use of our ...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS Not applicable..  ...</td>\n",
              "      <td>We believe our existing facilities, both owned...</td>\n",
              "      <td>. LEGAL PROCEEDINGS For a description of our m...</td>\n",
              "      <td>Our Class C capital stock has been listed on t...</td>\n",
              "      <td>.  Our employees are critical to our success a...</td>\n",
              "      <td>. If the U.S. dollar weakened by 10%, the amou...</td>\n",
              "      <td>. Google generates revenues primarily from adv...</td>\n",
              "      <td>. The ERP system is designed to accurately mai...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>Alphabet Inc.</td>\n",
              "      <td>2018</td>\n",
              "      <td>Brand advertising helps enhance users' awaren...</td>\n",
              "      <td>. Any increase in the unauthorized use of our ...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS Not applicable..  ...</td>\n",
              "      <td>We believe our existing facilities, both owned...</td>\n",
              "      <td>LEGAL PROCEEDINGS For a description of our mat...</td>\n",
              "      <td>Our Class C capital stock has been listed on t...</td>\n",
              "      <td>For example, we have seen an increase in YouTu...</td>\n",
              "      <td>. The change in the value recorded in AOCI wou...</td>\n",
              "      <td>. Nature of Operations and Summary of Signific...</td>\n",
              "      <td>. The effectiveness of our internal control ov...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>Microsoft Corporation</td>\n",
              "      <td>2021</td>\n",
              "      <td>Investing in the Future Our success is based o...</td>\n",
              "      <td>In addition, economic and political pressures ...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS We have received n...</td>\n",
              "      <td>The largest leased properties include space in...</td>\n",
              "      <td>. LEGAL PROCEEDINGS Refer to Note 15  Continge...</td>\n",
              "      <td>Our share repurchases may occur through open m...</td>\n",
              "      <td>These provisions require us to capitalize rese...</td>\n",
              "      <td>SENSITIVITY ANALYSIS The following table sets ...</td>\n",
              "      <td>Our products are generally sold with a right o...</td>\n",
              "      <td>Also, projections of any evaluation of effecti...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>Microsoft Corporation</td>\n",
              "      <td>2020</td>\n",
              "      <td>Investing in the Future Our success is based o...</td>\n",
              "      <td>In addition, economic and political pressures ...</td>\n",
              "      <td>UNRESOLVED STAFF COMMENTS We have received no ...</td>\n",
              "      <td>These facilities include approximately 10 mill...</td>\n",
              "      <td>. Ballmer et al, United States District Court ...</td>\n",
              "      <td>The above table excludes shares repurchased to...</td>\n",
              "      <td>The fair value of each reporting unit is estim...</td>\n",
              "      <td>Equity Securities held in our equity investmen...</td>\n",
              "      <td>We applied a modified retrospective approach t...</td>\n",
              "      <td>We are a public accounting firm registered wit...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>Microsoft Corporation</td>\n",
              "      <td>2019</td>\n",
              "      <td>Mr. Nadella also serves on the Board of Direct...</td>\n",
              "      <td>We will continue to make significant investmen...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS We have received n...</td>\n",
              "      <td>In addition, we own and lease space domestical...</td>\n",
              "      <td>. LEGAL PROCEEDINGS While not material to the ...</td>\n",
              "      <td>MARKET FOR REGISTRANTS COMMON EQUITY, RELATED ...</td>\n",
              "      <td>The fair value of each reporting unit is estim...</td>\n",
              "      <td>Equity Securities held in our equity investmen...</td>\n",
              "      <td>We adopted the standard effective July 1, 2019...</td>\n",
              "      <td>We are a public accounting firm registered wit...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>Microsoft Corporation</td>\n",
              "      <td>2018</td>\n",
              "      <td>This segment primarily comprises: Server produ...</td>\n",
              "      <td>In addition, economic and political pressures ...</td>\n",
              "      <td>.  ITEM 1B.. UNRESOLVE D STAFF COMMENTS We hav...</td>\n",
              "      <td>In addition, we own and lease space domestical...</td>\n",
              "      <td>. LEGAL PROCEEDINGS While not material to the ...</td>\n",
              "      <td>The above table excludes shares repurchased to...</td>\n",
              "      <td>Enterprise Services revenue increased $304 mil...</td>\n",
              "      <td>SENSITIVITY ANALYSIS The following table sets ...</td>\n",
              "      <td>Option and forward contracts are used to hedge...</td>\n",
              "      <td>We are a public accounting firm registered wit...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>Microsoft Corporation</td>\n",
              "      <td>2017</td>\n",
              "      <td>This segment primarily comprises: Server produ...</td>\n",
              "      <td>In addition, economic and political pressures ...</td>\n",
              "      <td>.  ITEM 1B.. UNRESOLVE D STAFF COMMENTS We hav...</td>\n",
              "      <td>In addition, we own and lease space domestical...</td>\n",
              "      <td>. LEGAL PROCEEDINGS While not material to the ...</td>\n",
              "      <td>The above table excludes shares repurchased to...</td>\n",
              "      <td>Enterprise Services revenue increased $304 mil...</td>\n",
              "      <td>SENSITIVITY ANALYSIS The following table sets ...</td>\n",
              "      <td>Option and forward contracts are used to hedge...</td>\n",
              "      <td>We are a public accounting firm registered wit...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>Costco</td>\n",
              "      <td>2021</td>\n",
              "      <td>Mr. Klauer was Senior Vice President, Non-Food...</td>\n",
              "      <td>The retail business is highly competitive.. . ...</td>\n",
              "      <td>.  Item 1BUnresolved Staff Comments None.</td>\n",
              "      <td>. Total square feet associated with distributi...</td>\n",
              "      <td>.  Item 3Legal Proceedings See discussion of L...</td>\n",
              "      <td>Item 5Market for Registrants Common Equity, R...</td>\n",
              "      <td>. The increase was across all categories, most...</td>\n",
              "      <td>Fluctuations in interest rates may affect the ...</td>\n",
              "      <td>These contracts meet the characteristics of de...</td>\n",
              "      <td>Based on its assessment, management has conclu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>Costco</td>\n",
              "      <td>2020</td>\n",
              "      <td>Net sales for e-commerce represented approxima...</td>\n",
              "      <td>The retail business is highly competitive.. . ...</td>\n",
              "      <td>.  Item 1BUnresolved Staff Comments None.</td>\n",
              "      <td>. Total square feet associated with distributi...</td>\n",
              "      <td>.  Item 3Legal Proceedings See discussion of L...</td>\n",
              "      <td>.  Item 5Market for Registrants Common Equity,...</td>\n",
              "      <td>. In April 2020, the Board of Directors increa...</td>\n",
              "      <td>Fluctuations in interest rates may affect the ...</td>\n",
              "      <td>. These contracts meet the characteristics of ...</td>\n",
              "      <td>Based on its assessment, management has conclu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>Costco</td>\n",
              "      <td>2019</td>\n",
              "      <td>Our annual fee for these memberships is $60 in...</td>\n",
              "      <td>The retail business is highly competitive.. . ...</td>\n",
              "      <td>.  Item 1BUnresolved Staff Comments None.</td>\n",
              "      <td>. Our executive offices are located in Issaqua...</td>\n",
              "      <td>.  Item 3Legal Proceedings See discussion of L...</td>\n",
              "      <td>.  Item 5Market for Registrants Common Equity,...</td>\n",
              "      <td>. Sales comparisons can also be particularly i...</td>\n",
              "      <td>Fluctuations in interest rates may affect the ...</td>\n",
              "      <td>The components of the deferred tax assets (lia...</td>\n",
              "      <td>During 2019 , management implemented our previ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>Costco</td>\n",
              "      <td>2018</td>\n",
              "      <td>Our annual fee for these memberships is $60 in...</td>\n",
              "      <td>The retail business is highly competitive.. . ...</td>\n",
              "      <td>.  Item 1BUnresolved Staff Comments None.</td>\n",
              "      <td>.  Item 2Properties Warehouse Properties At Se...</td>\n",
              "      <td>.  Item 3Legal Proceedings See discussion of L...</td>\n",
              "      <td>.  Item 5Market for Registrants Common Equity,...</td>\n",
              "      <td>Our primary requirement for capital is acquiri...</td>\n",
              "      <td>Fluctuations in interest rates may affect the ...</td>\n",
              "      <td>. Maturities of long-term debt during the next...</td>\n",
              "      <td>We expect that the remediation of this materia...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>Costco</td>\n",
              "      <td>2017</td>\n",
              "      <td>The Executive membership fee increased from $1...</td>\n",
              "      <td>The retail business is highly competitive.. . ...</td>\n",
              "      <td>.  Item 1BUnresolved Staff Comments None.</td>\n",
              "      <td>. We operate 24 depots, consisting of approxim...</td>\n",
              "      <td>.  Item 3Legal Proceedings See discussion of L...</td>\n",
              "      <td>.  Item 5Market for Registrants Common Equity,...</td>\n",
              "      <td>. Our Executive members qualify for a 2% rewar...</td>\n",
              "      <td>Fluctuations in interest rates may affect the ...</td>\n",
              "      <td>.  Item 8Financial Statements and Supplementar...</td>\n",
              "      <td>Item 9AControls and Procedures Disclosure Con...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>24</th>\n",
              "      <td>Pfizer</td>\n",
              "      <td>2021</td>\n",
              "      <td>. Governments globally may use a variety of me...</td>\n",
              "      <td>We produce, collect, process, store and transm...</td>\n",
              "      <td>We produce, collect, process, store and transm...</td>\n",
              "      <td>. We continue to advance our global workplace ...</td>\n",
              "      <td>Director of Zoetis Inc.. Group President, Pfiz...</td>\n",
              "      <td>The following summarizes purchases of our comm...</td>\n",
              "      <td>. The operational increase in emerging markets...</td>\n",
              "      <td>ITEM 7A.. Pfizer Inc.. 2021 Form 10-K . QUANT...</td>\n",
              "      <td>. In addition, the direct purchaser class plai...</td>\n",
              "      <td>2021 Form 10-K PART III . 2021 Form 10-K Repor...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>Pfizer</td>\n",
              "      <td>2020</td>\n",
              "      <td>. Information relating to corporate governance...</td>\n",
              "      <td>For IPRD assets, the risk of failure is signif...</td>\n",
              "      <td>For IPRD assets, the risk of failure is signif...</td>\n",
              "      <td>. We expect to relocate our global headquarter...</td>\n",
              "      <td>and the National Health Council.. Director of ...</td>\n",
              "      <td>2020 Form 10-K . As of February 23, 2021, ther...</td>\n",
              "      <td>At December 31, 2020, our remaining share-purc...</td>\n",
              "      <td>ITEM 7A.. Pfizer Inc.. 2020 Form 10-K . QUANT...</td>\n",
              "      <td>. In addition, the direct purchaser class plai...</td>\n",
              "      <td>Management assessed the effectiveness of the C...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>Pfizer</td>\n",
              "      <td>2019</td>\n",
              "      <td>Information relating to corporate governance a...</td>\n",
              "      <td>For IPRD assets, the risk of failure is signif...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS Not applicable..  ...</td>\n",
              "      <td>Pfizer continues to own and lease space around...</td>\n",
              "      <td>. LEGAL PROCEEDINGS Certain legal proceedings ...</td>\n",
              "      <td>(b)  These columns represent (i) 108,367 share...</td>\n",
              "      <td>.  ITEM 7.. MANAGEMENTS DISCUSSION AND ANALYSI...</td>\n",
              "      <td>2019 Form 10-K We borrow primarily on a long-t...</td>\n",
              "      <td>. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA ...</td>\n",
              "      <td>. Internal Control over Financial Reporting Ma...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>27</th>\n",
              "      <td>Pfizer</td>\n",
              "      <td>2018</td>\n",
              "      <td>As part of our business strategy, we are capit...</td>\n",
              "      <td>For IPRD assets, the risk of failure is signif...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS Not applicable..  ...</td>\n",
              "      <td>Pfizer continues to own and lease space around...</td>\n",
              "      <td>. LEGAL PROCEEDINGS Certain legal proceedings ...</td>\n",
              "      <td>. Additional information required by this item...</td>\n",
              "      <td>.  ITEM 7.. MANAGEMENTS DISCUSSION AND ANALYSI...</td>\n",
              "      <td>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT...</td>\n",
              "      <td>. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA ...</td>\n",
              "      <td>.  ITEM 9A.. Based on this evaluation, our pri...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>28</th>\n",
              "      <td>Pfizer</td>\n",
              "      <td>2017</td>\n",
              "      <td>Note: Some amounts in this 2016 Form 10-K may ...</td>\n",
              "      <td>For IPRD assets, the risk of failure is signif...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS Not applicable..  ...</td>\n",
              "      <td>Pfizer continues to own and lease space around...</td>\n",
              "      <td>. LEGAL PROCEEDINGS Certain legal proceedings ...</td>\n",
              "      <td>. On June 20, 2016, the accelerated share repu...</td>\n",
              "      <td>ITEM 7.. Pfizer Inc.. MANAGEMENTS DISCUSSION ...</td>\n",
              "      <td>.  ITEM 7A.. QUANTITATIVE AND QUALITATIVE DISC...</td>\n",
              "      <td>. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA ...</td>\n",
              "      <td>. CONTROLS AND PROCEDURES Disclosure Controls ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>29</th>\n",
              "      <td>PepsiCo</td>\n",
              "      <td>2021</td>\n",
              "      <td>. We are also required to comply with the Fore...</td>\n",
              "      <td>Many of our employees are covered by collectiv...</td>\n",
              "      <td>Table of Contents . We have received no writte...</td>\n",
              "      <td>. See Note 13 to our consolidated financial st...</td>\n",
              "      <td>Table of Contents . Legal Proceedings.. Busine...</td>\n",
              "      <td>For the remainder of 2022, the record dates fo...</td>\n",
              "      <td>The commingled funds are based on the publishe...</td>\n",
              "      <td>Included in Item 7.. .  Item 7A.. Managements ...</td>\n",
              "      <td>Item 8.. . Financial Statements and Supplemen...</td>\n",
              "      <td>. Beginning in the fourth quarter of 2021 and ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>30</th>\n",
              "      <td>PepsiCo</td>\n",
              "      <td>2020</td>\n",
              "      <td>. (Dole) and Ocean Spray Cranberries, Inc.. We...</td>\n",
              "      <td>Many of our employees are covered by collectiv...</td>\n",
              "      <td>Table of Contents .  Item 1B.. Unresolved Staf...</td>\n",
              "      <td>. Our principal executive office located in Pu...</td>\n",
              "      <td>. Legal Proceedings.. Business  Regulatory Mat...</td>\n",
              "      <td>On February 4, 2021, the Board of Directors de...</td>\n",
              "      <td>The allocation methodology is based on our for...</td>\n",
              "      <td>Included in Item 7.. .  Item 7A.. Managements ...</td>\n",
              "      <td>. Other Information.. Except as discussed, the...</td>\n",
              "      <td>. Except as discussed, there have been no chan...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>31</th>\n",
              "      <td>PepsiCo</td>\n",
              "      <td>2019</td>\n",
              "      <td>. (Dole) and Ocean Spray Cranberries, Inc.. We...</td>\n",
              "      <td>Many of these laws and regulations have differ...</td>\n",
              "      <td>. We have received no written comments regardi...</td>\n",
              "      <td>. Our principal executive office located in Pu...</td>\n",
              "      <td>. Legal Proceedings.. Business  Regulatory Mat...</td>\n",
              "      <td>. Issuer Purchases of Common Stock Period Tota...</td>\n",
              "      <td>The carrying value of indefinite-lived intangi...</td>\n",
              "      <td>Included in Item 7.. .  Item 7A.. Managements ...</td>\n",
              "      <td>Item 8.. . Financial Statements and Supplemen...</td>\n",
              "      <td>. In addition, in connection with our 2019 mul...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>PepsiCo</td>\n",
              "      <td>2018</td>\n",
              "      <td>. (Dole) and Ocean Spray Cranberries, Inc.. We...</td>\n",
              "      <td>Many of these laws and regulations have differ...</td>\n",
              "      <td>.  Item 1B.. Unresolved Staff Comments.. We ha...</td>\n",
              "      <td>Shared service centers in Winston-Salem, Nort...</td>\n",
              "      <td>. If the environmental authority determines PA...</td>\n",
              "      <td>Such shares may be repurchased in open market ...</td>\n",
              "      <td>. The allocation methodology is based on our f...</td>\n",
              "      <td>Included in Item 7.. .  Item 7A.. Managements ...</td>\n",
              "      <td>Item 8.. . Financial Statements and Supplemen...</td>\n",
              "      <td>. Except as discussed, there have been no chan...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>33</th>\n",
              "      <td>PepsiCo</td>\n",
              "      <td>2017</td>\n",
              "      <td>These activities principally involve: developm...</td>\n",
              "      <td>Many of these laws and regulations have differ...</td>\n",
              "      <td>.  Item 1B.. Unresolved Staff Comments.. We ha...</td>\n",
              "      <td>.  Item 2.. We believe that our properties gen...</td>\n",
              "      <td>. Legal Proceedings.. In October 2017, the Sup...</td>\n",
              "      <td>Such shares may be repurchased in open market ...</td>\n",
              "      <td>. The allocation methodology is based on our f...</td>\n",
              "      <td>Included in Item 7.. .  Item 7A.. Managements ...</td>\n",
              "      <td>Item 8.. . Financial Statements and Supplemen...</td>\n",
              "      <td>. Based on that evaluation, our management con...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>34</th>\n",
              "      <td>AbbVie</td>\n",
              "      <td>2021</td>\n",
              "      <td>AbbVies medical device products are subject to...</td>\n",
              "      <td>. The manufacture of many of AbbVie's products...</td>\n",
              "      <td>.  ITEM 1B.. UNRESOLVED STAFF COMMENTS None.</td>\n",
              "      <td>AbbVie believes its facilities are suitable an...</td>\n",
              "      <td>. LEGAL PROCEEDINGS Information pertaining to ...</td>\n",
              "      <td>In addition to AbbVie shares repurchased on th...</td>\n",
              "      <td>Valuation of Goodwill and Intangible Assets Ab...</td>\n",
              "      <td>Certain derivative instruments are used when a...</td>\n",
              "      <td>In October 2021, the May 2021 declaratory judg...</td>\n",
              "      <td>Based on that assessment, management concluded...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>35</th>\n",
              "      <td>AbbVie</td>\n",
              "      <td>2020</td>\n",
              "      <td>AbbVie's capital expenditures for pollution co...</td>\n",
              "      <td>. The manufacture of many of AbbVie's products...</td>\n",
              "      <td>.  ITEM 1B.. UNRESOLVED STAFF COMMENTS None.</td>\n",
              "      <td>In addition to the above, AbbVie has other man...</td>\n",
              "      <td>. LEGAL PROCEEDINGS Information pertaining to ...</td>\n",
              "      <td>. In addition to AbbVie shares repurchased on ...</td>\n",
              "      <td>Valuation of Goodwill and Intangible Assets Ab...</td>\n",
              "      <td>As a result, any foreign currency translation ...</td>\n",
              "      <td>The following table summarizes benefit plan in...</td>\n",
              "      <td>There were no changes in AbbVie's internal con...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>36</th>\n",
              "      <td>AbbVie</td>\n",
              "      <td>2019</td>\n",
              "      <td>Allergan markets a portfolio of brands and pro...</td>\n",
              "      <td>. AbbVie also intends to assume all the existi...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS  None..  ITEM 1B.</td>\n",
              "      <td>. PROPERTIES  AbbVie's corporate offices are l...</td>\n",
              "      <td>. LEGAL PROCEEDINGS  Information pertaining to...</td>\n",
              "      <td>Performance Graph The following graph compares...</td>\n",
              "      <td>This action does not impact any of the approve...</td>\n",
              "      <td>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT...</td>\n",
              "      <td>Allergan markets a portfolio of brands and pro...</td>\n",
              "      <td>The report of AbbVie's independent registered ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>37</th>\n",
              "      <td>AbbVie</td>\n",
              "      <td>2018</td>\n",
              "      <td>. Managed care providers (for example, health ...</td>\n",
              "      <td>.  Biologics carry unique risks and uncertaint...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS  None..  ITEM 1B.</td>\n",
              "      <td>PROPERTIES  AbbVie's corporate offices are loc...</td>\n",
              "      <td>.  ITEM 3.. LEGAL PROCEEDINGS  Information per...</td>\n",
              "      <td>Dividends On November 2, 2018 , AbbVie's board...</td>\n",
              "      <td>IPRD acquired in transactions that are not bus...</td>\n",
              "      <td>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT...</td>\n",
              "      <td>2018 Form 10-K  |   53 Recent Accounting Pro...</td>\n",
              "      <td>2018 Form 10-K  |   89 Report of independent...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>38</th>\n",
              "      <td>AbbVie</td>\n",
              "      <td>2017</td>\n",
              "      <td>.  VENCLEXTA (venetoclax) is approved to treat...</td>\n",
              "      <td>. The potential for continuing 14    |  2017 F...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS  None..  ITEM 1B.</td>\n",
              "      <td>PROPERTIES  AbbVie's corporate offices are loc...</td>\n",
              "      <td>.  ITEM 3.. LEGAL PROCEEDINGS  Information per...</td>\n",
              "      <td>Moreover, if AbbVie determines to pay any divi...</td>\n",
              "      <td>The increase in the effective tax rate for 201...</td>\n",
              "      <td>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT...</td>\n",
              "      <td>The effective income tax rate in 2016 included...</td>\n",
              "      <td>/s/ Ernst  Young LLP Chicago, Illinois Februar...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>39</th>\n",
              "      <td>Coca-Cola</td>\n",
              "      <td>2021</td>\n",
              "      <td>These include companies that, like our Company...</td>\n",
              "      <td>In the conduct of our business, we rely on rel...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS Not applicable..  ...</td>\n",
              "      <td>. However, management believes that additional...</td>\n",
              "      <td>. On January 23, 2013, the Chartis insurers fi...</td>\n",
              "      <td>As of February 18, 2022, there were 191,391 sh...</td>\n",
              "      <td>. In the fourth quarter of 2020, the Company s...</td>\n",
              "      <td>. We use derivative financial instruments to f...</td>\n",
              "      <td>This includes certain pricing models, discount...</td>\n",
              "      <td>. CONTROLS AND PROCEDURES Evaluation of Disclo...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>40</th>\n",
              "      <td>Coca-Cola</td>\n",
              "      <td>2020</td>\n",
              "      <td>These include companies that, like our Company...</td>\n",
              "      <td>In the conduct of our business, we rely on rel...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS Not applicable..  ...</td>\n",
              "      <td>. The office complex also includes several oth...</td>\n",
              "      <td>. Some or all of this amount would be refunded...</td>\n",
              "      <td>This column discloses the number of shares ava...</td>\n",
              "      <td>Refer to the heading \"Beverage Volume\" below.....</td>\n",
              "      <td>. These values include derivative instruments ...</td>\n",
              "      <td>This includes certain pricing models, discount...</td>\n",
              "      <td>. Changes in Internal Control Over Financial R...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>41</th>\n",
              "      <td>Coca-Cola</td>\n",
              "      <td>2019</td>\n",
              "      <td>We are also subject to various federal, state ...</td>\n",
              "      <td>In the conduct of our business, we rely on rel...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS Not applicable..  ...</td>\n",
              "      <td>. However, management believes that additional...</td>\n",
              "      <td>. This decision effectively reduced the IRS' p...</td>\n",
              "      <td>. In 2019, the Dow Jones Food  Beverage Index ...</td>\n",
              "      <td>Refer to the heading \"Beverage Volume\" below.....</td>\n",
              "      <td>. These values include derivative instruments ...</td>\n",
              "      <td>. This difference is not amortized.. Refer to ...</td>\n",
              "      <td>Changes in Internal Control Over Financial Rep...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>42</th>\n",
              "      <td>Coca-Cola</td>\n",
              "      <td>2018</td>\n",
              "      <td>. In addition, certain U.S. bottlers that were...</td>\n",
              "      <td>In the conduct of our business, we rely on rel...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS Not applicable..  ...</td>\n",
              "      <td>. We also own an office and retail building at...</td>\n",
              "      <td>. The Wisconsin Case initially was stayed, pen...</td>\n",
              "      <td>. and US Foods Holding Corp.. MARKET FOR REGIS...</td>\n",
              "      <td>Refer to the heading \"Beverage Volume\" below.....</td>\n",
              "      <td>. These values include derivative instruments ...</td>\n",
              "      <td>. This difference is not amortized.. 2  Expect...</td>\n",
              "      <td>Report of Management on Internal Control Over ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>43</th>\n",
              "      <td>Coca-Cola</td>\n",
              "      <td>2017</td>\n",
              "      <td>. In addition, certain U.S. bottlers that were...</td>\n",
              "      <td>The final amounts may be significantly affecte...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS Not applicable..  ...</td>\n",
              "      <td>. We also own an office and retail building at...</td>\n",
              "      <td>. The Wisconsin Case initially was stayed, pen...</td>\n",
              "      <td>This column discloses the number of shares pur...</td>\n",
              "      <td>Refer to the heading \"Beverage Volume\" below.....</td>\n",
              "      <td>. These values include derivative instruments ...</td>\n",
              "      <td>. This difference is not amortized.. 2  Expect...</td>\n",
              "      <td>. Management has excluded from the scope of it...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>44</th>\n",
              "      <td>Mastercard</td>\n",
              "      <td>2021</td>\n",
              "      <td>. Financial and other material information is ...</td>\n",
              "      <td>As cyber-threats continue to evolve, we may be...</td>\n",
              "      <td>.  Item 1B.. Unresolved staff comments Not app...</td>\n",
              "      <td>Properties We own our corporate headquarters, ...</td>\n",
              "      <td>.  Item 3.. Legal proceedings Refer to Note 13...</td>\n",
              "      <td>. Mastercards Class B common stock is not publ...</td>\n",
              "      <td>Managements discussion and analysis of financi...</td>\n",
              "      <td>Management monitors risk exposures on an ongoi...</td>\n",
              "      <td>The remaining RSUs will be settled in shares o...</td>\n",
              "      <td>. PricewaterhouseCoopers LLP, an independent r...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>45</th>\n",
              "      <td>Mastercard</td>\n",
              "      <td>2020</td>\n",
              "      <td>Financial and other material information is ro...</td>\n",
              "      <td>As cyber-threats continue to evolve, we may be...</td>\n",
              "      <td>.  Item 1B.. Unresolved staff comments Not app...</td>\n",
              "      <td>Properties We own our corporate headquarters, ...</td>\n",
              "      <td>.  Item 3.. Legal proceedings Refer to Note 13...</td>\n",
              "      <td>Mastercards Class B common stock is not public...</td>\n",
              "      <td>. Managements discussion and analysis of finan...</td>\n",
              "      <td>The Company did not have any outstanding short...</td>\n",
              "      <td>In our opinion, the consolidated financial sta...</td>\n",
              "      <td>. PricewaterhouseCoopers LLP, an independent r...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>46</th>\n",
              "      <td>Mastercard</td>\n",
              "      <td>2019</td>\n",
              "      <td>Business      .  Item 1.</td>\n",
              "      <td>Item 1A.. Risk factors</td>\n",
              "      <td>Unresolved staff comments      .  Item 1B.</td>\n",
              "      <td>Item 2.. Properties</td>\n",
              "      <td>Legal proceedings      .  Item 3.</td>\n",
              "      <td>Mastercards Class B common stock is not public...</td>\n",
              "      <td>This    includes 2 percentage points of growth...</td>\n",
              "      <td>To manage this risk, we enter into foreign exc...</td>\n",
              "      <td>The remaining RSUs will be settled in shares o...</td>\n",
              "      <td>. Changes in Internal Control over Financial R...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>47</th>\n",
              "      <td>Mastercard</td>\n",
              "      <td>2018</td>\n",
              "      <td>. Financial and other material information is ...</td>\n",
              "      <td>As cyber-threats continue to evolve, we may be...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS Not applicable..  ...</td>\n",
              "      <td>. These facilities primarily consist of corpor...</td>\n",
              "      <td>. LEGAL PROCEEDINGS Refer to Note 12 (Accrued ...</td>\n",
              "      <td>. Mastercards Class B common stock is not publ...</td>\n",
              "      <td>. 2 Represents the foreign currency translatio...</td>\n",
              "      <td>. The fair value and maturity distribution of ...</td>\n",
              "      <td>. In February 2013, the district court granted...</td>\n",
              "      <td>. PricewaterhouseCoopers LLP, an independent r...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>48</th>\n",
              "      <td>Mastercard</td>\n",
              "      <td>2017</td>\n",
              "      <td>. Financial and other material information is ...</td>\n",
              "      <td>As cyber-threats continue to evolve, we may be...</td>\n",
              "      <td>. UNRESOLVED STAFF COMMENTS Not applicable..  ...</td>\n",
              "      <td>. Our leased properties in the United States a...</td>\n",
              "      <td>. LEGAL PROCEEDINGS Refer to Notes 10 (Accrued...</td>\n",
              "      <td>. This program will become effective after com...</td>\n",
              "      <td>. The following tables reconcile our as-report...</td>\n",
              "      <td>. The effect of a hypothetical 10% adverse cha...</td>\n",
              "      <td>As of December 31, 2017 , Mastercard had accru...</td>\n",
              "      <td>The President and Chief Executive Officer and ...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-ce7f6355-1878-4631-8781-f8d0d55eb624')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-ce7f6355-1878-4631-8781-f8d0d55eb624 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-ce7f6355-1878-4631-8781-f8d0d55eb624');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 24
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "#### 5. Appling HuggingFace Model"
      ],
      "metadata": {
        "id": "6_2kKqyqr9em"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install --q transformers -q"
      ],
      "metadata": {
        "id": "QohLYwy5tEOK"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from transformers import pipeline"
      ],
      "metadata": {
        "id": "cjynnkaEtGri"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Used to summarize text\n",
        "def text_summarizer(summarizer, text):\n",
        "  \"\"\"\n",
        "  Returns a Summarized string for text\n",
        "\n",
        "  Parameters:\n",
        "  -----------\n",
        "  summarizer: transformers.pipelines - Huggingface Model object for Summarization.\n",
        "  text: str - String to be summarized\n",
        "  \"\"\"\n",
        "\n",
        "  sumr = summarizer(text, do_sample=False, truncation=True)\n",
        "  \n",
        "  return sumr[0][list(sumr[0].keys())[0]]"
      ],
      "metadata": {
        "id": "7HgpgFTFj9Qk"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Used to analyze-sentiment text\n",
        "def text_classifier(classifier, text):\n",
        "  \"\"\"\n",
        "  Returns a Dictionary with Sentiment\n",
        "\n",
        "  Parameters:\n",
        "  -----------\n",
        "  classifier: transformers.pipelines - Huggingface Model object for Classification.\n",
        "  text: str - String to be classified\n",
        "  \"\"\"\n",
        "\n",
        "  res = classifier(text, padding=True, truncation=True)\n",
        "  \n",
        "  return res[0]"
      ],
      "metadata": {
        "id": "DhkiXgeXstvZ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Used to summarize text and returns a dataframe\n",
        "def final_dataframe(text_function, model, df, exclude_columns):\n",
        "  \"\"\"\n",
        "  Returns a Dataframe having applied Huggingface model\n",
        "\n",
        "  Parameters:\n",
        "  -----------\n",
        "  text_function: Python function.\n",
        "  model: transformers.pipelines - Huggingface Model object for Classification.\n",
        "  df : pandas.DataFrame - DataFrame on which you wish to perform Text-Preprocessing.\n",
        "  exclude_columns : int - Which column to exclude from Dataframe.\n",
        "  \"\"\"\n",
        "\n",
        "  temp1 = df.iloc[:,:exclude_columns]\n",
        "  arr = df.iloc[:,exclude_columns:].to_numpy()\n",
        "  columns=list(df.iloc[:,exclude_columns:].columns)\n",
        "\n",
        "  for row in range(len(arr)):\n",
        "    for col in range(len(arr[0])):\n",
        "      arr[row][col] = text_function(model, arr[row][col])\n",
        "\n",
        "  temp2 = pd.DataFrame(arr, columns=columns)\n",
        "\n",
        "  return pd.concat([temp1, temp2], axis=1)"
      ],
      "metadata": {
        "id": "5HTcxXl5-cBL"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "summarizer = pipeline('summarization', model=SUMARIZED_MODEL)\n",
        "\n",
        "final = final_dataframe(text_summarizer, summarizer, clean, 2)\n",
        "final.to_csv('./datasets/'+ SUMARIZED_MODEL.replace('/', '_') +'.csv', index=False)\n",
        "pd.read_csv('./datasets/'+ SUMARIZED_MODEL.replace('/', '_') +'.csv').head()"
      ],
      "metadata": {
        "id": "dc79pFitjX4a"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "classifier = pipeline('sentiment-analysis', model=CLASSIFIED_MODEL)\n",
        "\n",
        "final = final_dataframe(text_classifier, classifier, clean, 2)\n",
        "final.to_csv('./datasets/'+ CLASSIFIED_MODEL.replace('/', '_') +'.csv', index=False)\n",
        "pd.read_csv('./datasets/'+ CLASSIFIED_MODEL.replace('/', '_') +'.csv').head()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 531
        },
        "id": "hmF0zA8lE9Vo",
        "outputId": "f222d1c8-9dd6-4424-930c-06966f326660"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "  Company Reporting_Date                                                  1  \\\n",
              "0    Meta           2021  {'label': 'POSITIVE', 'score': 0.9124663472175...   \n",
              "1    Meta           2020  {'label': 'POSITIVE', 'score': 0.5144032835960...   \n",
              "2    Meta           2019  {'label': 'POSITIVE', 'score': 0.9474074244499...   \n",
              "3    Meta           2018  {'label': 'POSITIVE', 'score': 0.980543315410614}   \n",
              "4    Meta           2017  {'label': 'POSITIVE', 'score': 0.880610466003418}   \n",
              "\n",
              "                                                  1A  \\\n",
              "0  {'label': 'NEGATIVE', 'score': 0.9969049096107...   \n",
              "1  {'label': 'NEGATIVE', 'score': 0.9977102279663...   \n",
              "2  {'label': 'NEGATIVE', 'score': 0.9979555606842...   \n",
              "3  {'label': 'NEGATIVE', 'score': 0.9987450838088...   \n",
              "4  {'label': 'NEGATIVE', 'score': 0.9986382126808...   \n",
              "\n",
              "                                                  1B  \\\n",
              "0  {'label': 'NEGATIVE', 'score': 0.9989053010940...   \n",
              "1  {'label': 'NEGATIVE', 'score': 0.9989053010940...   \n",
              "2  {'label': 'NEGATIVE', 'score': 0.9989053010940...   \n",
              "3  {'label': 'NEGATIVE', 'score': 0.9989053010940...   \n",
              "4  {'label': 'NEGATIVE', 'score': 0.9989053010940...   \n",
              "\n",
              "                                                   2  \\\n",
              "0  {'label': 'POSITIVE', 'score': 0.9971873164176...   \n",
              "1  {'label': 'POSITIVE', 'score': 0.9943506717681...   \n",
              "2  {'label': 'POSITIVE', 'score': 0.9960851669311...   \n",
              "3  {'label': 'POSITIVE', 'score': 0.9918457865715...   \n",
              "4  {'label': 'NEGATIVE', 'score': 0.9125710129737...   \n",
              "\n",
              "                                                   3  \\\n",
              "0  {'label': 'NEGATIVE', 'score': 0.9940243363380...   \n",
              "1  {'label': 'NEGATIVE', 'score': 0.9984756112098...   \n",
              "2  {'label': 'NEGATIVE', 'score': 0.9946576952934...   \n",
              "3  {'label': 'NEGATIVE', 'score': 0.9970108270645...   \n",
              "4  {'label': 'NEGATIVE', 'score': 0.9956183433532...   \n",
              "\n",
              "                                                   5  \\\n",
              "0  {'label': 'NEGATIVE', 'score': 0.9989150762557...   \n",
              "1  {'label': 'NEGATIVE', 'score': 0.9985986351966...   \n",
              "2  {'label': 'NEGATIVE', 'score': 0.9978011250495...   \n",
              "3  {'label': 'NEGATIVE', 'score': 0.9985345602035...   \n",
              "4  {'label': 'NEGATIVE', 'score': 0.9982483386993...   \n",
              "\n",
              "                                                   7  \\\n",
              "0  {'label': 'NEGATIVE', 'score': 0.9973219037055...   \n",
              "1  {'label': 'NEGATIVE', 'score': 0.9937828183174...   \n",
              "2  {'label': 'NEGATIVE', 'score': 0.9985656142234...   \n",
              "3  {'label': 'NEGATIVE', 'score': 0.9932865500450...   \n",
              "4  {'label': 'NEGATIVE', 'score': 0.9915756583213...   \n",
              "\n",
              "                                                  7A  \\\n",
              "0  {'label': 'NEGATIVE', 'score': 0.9965571165084...   \n",
              "1  {'label': 'NEGATIVE', 'score': 0.9981203675270...   \n",
              "2  {'label': 'NEGATIVE', 'score': 0.9973078966140...   \n",
              "3  {'label': 'NEGATIVE', 'score': 0.9960965514183...   \n",
              "4  {'label': 'NEGATIVE', 'score': 0.9975601434707...   \n",
              "\n",
              "                                                   8  \\\n",
              "0  {'label': 'NEGATIVE', 'score': 0.9949929118156...   \n",
              "1  {'label': 'NEGATIVE', 'score': 0.9926292896270...   \n",
              "2  {'label': 'NEGATIVE', 'score': 0.9868752956390...   \n",
              "3  {'label': 'NEGATIVE', 'score': 0.9974138736724...   \n",
              "4  {'label': 'NEGATIVE', 'score': 0.9949482679367...   \n",
              "\n",
              "                                                  9A  \n",
              "0  {'label': 'NEGATIVE', 'score': 0.9525972008705...  \n",
              "1  {'label': 'NEGATIVE', 'score': 0.934410035610199}  \n",
              "2  {'label': 'NEGATIVE', 'score': 0.9530308246612...  \n",
              "3  {'label': 'NEGATIVE', 'score': 0.9812654852867...  \n",
              "4  {'label': 'NEGATIVE', 'score': 0.9071258306503...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-19985080-2b57-4324-9597-f95e6e258872\">\n",
              "    <div class=\"colab-df-container\">\n",
              "      <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>Company</th>\n",
              "      <th>Reporting_Date</th>\n",
              "      <th>1</th>\n",
              "      <th>1A</th>\n",
              "      <th>1B</th>\n",
              "      <th>2</th>\n",
              "      <th>3</th>\n",
              "      <th>5</th>\n",
              "      <th>7</th>\n",
              "      <th>7A</th>\n",
              "      <th>8</th>\n",
              "      <th>9A</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2021</td>\n",
              "      <td>{'label': 'POSITIVE', 'score': 0.9124663472175...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9969049096107...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9989053010940...</td>\n",
              "      <td>{'label': 'POSITIVE', 'score': 0.9971873164176...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9940243363380...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9989150762557...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9973219037055...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9965571165084...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9949929118156...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9525972008705...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2020</td>\n",
              "      <td>{'label': 'POSITIVE', 'score': 0.5144032835960...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9977102279663...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9989053010940...</td>\n",
              "      <td>{'label': 'POSITIVE', 'score': 0.9943506717681...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9984756112098...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9985986351966...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9937828183174...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9981203675270...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9926292896270...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.934410035610199}</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2019</td>\n",
              "      <td>{'label': 'POSITIVE', 'score': 0.9474074244499...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9979555606842...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9989053010940...</td>\n",
              "      <td>{'label': 'POSITIVE', 'score': 0.9960851669311...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9946576952934...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9978011250495...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9985656142234...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9973078966140...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9868752956390...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9530308246612...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2018</td>\n",
              "      <td>{'label': 'POSITIVE', 'score': 0.980543315410614}</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9987450838088...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9989053010940...</td>\n",
              "      <td>{'label': 'POSITIVE', 'score': 0.9918457865715...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9970108270645...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9985345602035...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9932865500450...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9960965514183...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9974138736724...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9812654852867...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Meta</td>\n",
              "      <td>2017</td>\n",
              "      <td>{'label': 'POSITIVE', 'score': 0.880610466003418}</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9986382126808...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9989053010940...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9125710129737...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9956183433532...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9982483386993...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9915756583213...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9975601434707...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9949482679367...</td>\n",
              "      <td>{'label': 'NEGATIVE', 'score': 0.9071258306503...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "      <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-19985080-2b57-4324-9597-f95e6e258872')\"\n",
              "              title=\"Convert this dataframe to an interactive table.\"\n",
              "              style=\"display:none;\">\n",
              "        \n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M0 0h24v24H0V0z\" fill=\"none\"/>\n",
              "    <path d=\"M18.56 5.44l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94zm-11 1L8.5 8.5l.94-2.06 2.06-.94-2.06-.94L8.5 2.5l-.94 2.06-2.06.94zm10 10l.94 2.06.94-2.06 2.06-.94-2.06-.94-.94-2.06-.94 2.06-2.06.94z\"/><path d=\"M17.41 7.96l-1.37-1.37c-.4-.4-.92-.59-1.43-.59-.52 0-1.04.2-1.43.59L10.3 9.45l-7.72 7.72c-.78.78-.78 2.05 0 2.83L4 21.41c.39.39.9.59 1.41.59.51 0 1.02-.2 1.41-.59l7.78-7.78 2.81-2.81c.8-.78.8-2.07 0-2.86zM5.41 20L4 18.59l7.72-7.72 1.47 1.35L5.41 20z\"/>\n",
              "  </svg>\n",
              "      </button>\n",
              "      \n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      flex-wrap:wrap;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "      <script>\n",
              "        const buttonEl =\n",
              "          document.querySelector('#df-19985080-2b57-4324-9597-f95e6e258872 button.colab-df-convert');\n",
              "        buttonEl.style.display =\n",
              "          google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "        async function convertToInteractive(key) {\n",
              "          const element = document.querySelector('#df-19985080-2b57-4324-9597-f95e6e258872');\n",
              "          const dataTable =\n",
              "            await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                     [key], {});\n",
              "          if (!dataTable) return;\n",
              "\n",
              "          const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "            '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "            + ' to learn more about interactive tables.';\n",
              "          element.innerHTML = '';\n",
              "          dataTable['output_type'] = 'display_data';\n",
              "          await google.colab.output.renderOutput(dataTable, element);\n",
              "          const docLink = document.createElement('div');\n",
              "          docLink.innerHTML = docLinkHtml;\n",
              "          element.appendChild(docLink);\n",
              "        }\n",
              "      </script>\n",
              "    </div>\n",
              "  </div>\n",
              "  "
            ]
          },
          "metadata": {},
          "execution_count": 34
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "x5T_BFRw5HK0"
      },
      "execution_count": null,
      "outputs": []
    }
  ],
  "metadata": {
    "colab": {
      "provenance": [],
      "collapsed_sections": [
        "c5NdRZ_Iq227",
        "bYywltLaq-RO",
        "oqR0hRpLrKHw",
        "MFxhmLJxrWQv",
        "6_2kKqyqr9em"
      ],
      "include_colab_link": true
    },
    "kernelspec": {
      "display_name": "Python 3.10.6 ('mi': venv)",
      "language": "python",
      "name": "python3"
    },
    "language_info": {
      "codemirror_mode": {
        "name": "ipython",
        "version": 3
      },
      "file_extension": ".py",
      "mimetype": "text/x-python",
      "name": "python",
      "nbconvert_exporter": "python",
      "pygments_lexer": "ipython3",
      "version": "3.10.6"
    },
    "vscode": {
      "interpreter": {
        "hash": "7881097960fc3e77119f32b1ae72960c65c17defcfb8b5058d4576fcdb5c630a"
      }
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}